pocketful logo
Samrat Pharmachem Ltd logo

Samrat Pharmachem Ltd

NSE: BSE: 530125

₹211.80

(1.36%)

Sat, 28 Mar 2026, 00:53 am

mtf coin illustrationMTF 5x

Samrat Pharmachem Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    60.45

  • Net Profit

    7.11

  • P/B

    1.35

  • Sector P/E

    40.02

  • P/E

    13.59

  • EV/EBITDA

    9.50

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.07

  • ROCE (Industry)

    20.49

  • RONW (Industry)

    17.59

  • ROE

    10.39

  • ROCE

    13.60

  • Debt/Equity

    0.13

  • EPS (TTM)

    0

  • Dividend Yield

    0.51

  • Book Value

    228.74

  • Interest Cover

    15.75

Analysis

all

thumbs up icon

Pros

  • Samrat Pharmachem is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Samrat Pharmachem is profitable, therefore cash runway is not a concern.
  • Samrat Pharmachem is profitable, therefore cash runway is not a concern.
  • Debt is covered by short term assets, assets are 3.7x debt.
  • Samrat Pharmachem's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Samrat Pharmachem's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Samrat Pharmachem's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Operating cash flow is negative therefore debt is not well covered.
  • The level of debt compared to net worth has increased over the past 5 years (26% vs 48.3% today).
  • Samrat Pharmachem's level of debt (48.3%) compared to net worth is high (greater than 40%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters49.0949.0949.0949.0949.09
FII00000
DII003.2400
Public50.9150.9147.6750.9150.91
Government00000

Read More

Technical Analysis

RSI

42.48

MACD

-3.20

50 DMA

211.96

200 DMA

281.01

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic332.87277.27243.33221.67187.73166.07110.47
Fibonacci277.27256.03242.91221.67200.43187.31166.07
Camarilla224.69219.59214.50221.67204.30199.21194.11

Pivots Level: Classic

R3

+111.20

332.87

R2

+55.60

277.27

R1

+21.67

243.33

221.67
221.67
Pivot Point
LTP: 195.65

S1

-33.93

187.73

S2

-55.60

166.07

S3

-111.20

110.47

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    204.64

  • 20-EMA

    207.18

  • 30-EMA

    209.41

  • 50-EMA

    215.17

  • 100-EMA

    234.36

  • 200-EMA

    269.48

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 Feb 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
18 Aug 2025dividendFinal Dividend - Rs. - 118 Sept 2025
30 May 2025dividend₹1.00 Dividend /Share18 Sept 2025
30 May 2025agm
19 Aug 2024dividendFinal Dividend - Rs. - 119 Sept 2024
30 May 2024agm
30 May 2024dividend₹1.00 Dividend /Share19 Sept 2024
18 Aug 2023dividendDividend - Rs. - 118 Sept 2023
30 May 2023dividend₹1.00 Dividend /Share18 Sept 2023

Read More

Peer Comparison

Samrat Pharmachem Ltd logo

Samrat Pharmachem Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Samrat Pharmachem Ltd About

Samrat Pharmachem is principal activities are manufacturing and selling chemicals. The shares of the Company are listed on stock exchanges in India.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1992

Headquarters

CEO

Lalit Mehta

Employees

Contact

Website icon

Website

http://www.samratpharmachem.com

Email icon

Email

contact@samratpharmachem.in

Phone icon

Phone

91-2646-220774

Location icon

Location

Plot No A2/3445, GIDC Phase IV, Ankleshwar, Gujarat, 393002

Read More

Samrat Pharmachem Ltd Company History

YearHistory
1994
  • The Company achieved a turnover of Rs.153.51 lacs and cash profit of Rs 8.79 lacs during the five month period ended 31st August.
  • The Company achieved direct and indirect exports worth Rs.35.59 lacs for the year ended March.
  • The Company achieved direct exports worth Rs.12.24 lacs from April to August.
2008
  • The company introduced an E-mail ID for Investors Complaints: [email protected]
2013
  • Samrat Pharmachem Ltd changed its Corporate Office Address to 701 / 702, Business Square, M. A. Road, Andheri (West), Mumbai - 400058.
2021
  • SPL received Authorized Economic Operator (AEO) Certificate from Indian Customs.
2023
  • SPL received FDA Licence.
  • SPL received Good Manufacturing Practices (GMP) & Good Laboratory Practices (GLP) Certificates from FDA.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GOLECHHA GLOBAL FINANCE LIMITEDSell16000426.1609 Sept 2024
SETU SECURITIES PVT. LTD.Sell15602341.6507 Aug 2023
SETU SECURITIES PVT. LTD.Buy15602344.4307 Aug 2023
ALERT CONSULTANTS & CREDIT PRIVATE LIMITEDSell21769345.7407 Aug 2023
GOLECHHA GLOBAL FINANCE LIMITEDSell23630405.8227 Jul 2023
HARISHKUMARGUPTABuy22000629.218 Aug 2022
MALA R BHAVNANISell28294454.5310 Jan 2022
ADVANI PRIVATE LIMITEDBuy68000404.2207 Jan 2022
MALA R BHAVNANISell78000404.4507 Jan 2022
TINA GOYALBuy18800322.5223 Dec 2021

Read More

Samrat Pharmachem Ltd News

Samrat Pharmachem Board Meet on May 30 for FY26 Results

Samrat Pharmachem Limited has scheduled its board meeting for May 30, 2026, to consider and approve audited standalone financial results for FY26 under Indian Accounting Standards.

25 Mar 2026

companies

Samrat Pharmachem Q3 FY26 Loss Widens to Rs 45.95 Lakhs

Samrat Pharmachem Limited reported a net loss of Rs 45.95 lakhs for Q3 FY26 compared to a profit of Rs 278.48 lakhs in Q3 FY25. Revenue remained flat at Rs 6,382.71 lakhs versus Rs 6,366.53 lakhs year-on-year.

18 Feb 2026

co actions results

Samrat Pharmachem's Credit Rating Downgraded by Crisil to BB/Negative from BBB-/Stable

Crisil downgraded Samrat Pharmachem Limited's bank facilities rating to Crisil BB/Negative/Crisil A4+ from Crisil BBB-/Stable/Crisil A3, affecting Rs 30 crore of total bank loan facilities. The downgrade reflects deterioration in the company's business risk profile, led by decline in operating margin to negative 0.14% in H1 FY2026, despite maintaining strong capital structure with low debt reliance.

02 Dec 2025

stock

Samrat Pharmachem Reports Loss in Q2 FY26 Despite Revenue Growth

Samrat Pharmachem Limited posted a net loss of Rs 58.73 lakhs for Q2 ended September 30, 2025, despite revenue growth to Rs 7,887.03 lakhs from Rs 7,172.22 lakhs in the same quarter last year. The pharmaceutical chemicals manufacturer's half-year loss widened to Rs 81.62 lakhs compared to a profit of Rs 472.66 lakhs in the previous year, with earnings per share declining to negative Rs 2.64.

15 Nov 2025

earnings

Samrat Pharmachem Shareholders Approve Re. 1 Per Share Dividend for FY 2024-25

Samrat Pharmachem Limited shareholders approved a dividend of Re. 1 per share (10%) for financial year 2024-25 at the company's 33rd Annual General Meeting held on September 25, 2025. The meeting was conducted through video conferencing and other audio-visual means. The dividend applies to equity shares of Rs. 10 each.

27 Sept 2025

corporate action

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800